Question normal

For us younger trainees, CTA seems like the new kid on the block in the area of noninvasive cardiovascular testing. The PROMISE trial seems to suggest that it has a role in the evaluation of CAD, at least leading to fewer catheterizations. On other hand, many clinicians like the functional part of more widely used tests. How should we think about its role in the tool kit?